Companies: 10,795·Total market cap: $144.5T
MedMira Inc.

MedMira Inc.

MIR.VTSXVHealthcare● Active
$0.06
+$0.00(+0.00%)
Market Cap$42103832
P/E Ratio
52W High$0.11
52W Low$0.05
Overview

MedMira Inc.(MIR.V)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · MIR.V · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-0.01mir.v eps ttm · mir.v earnings per shareEarnings history
PE Ratio (TTM)mir.v pe ratio ttm · mir.v price to earningsPE Ratio deep dive
Revenue (TTM)188496.00mir.v revenue ttm · mir.v annual revenueFull revenue history
Dividend Yield不分红does mir.v pay dividends · mir.v dividend yieldDividend history
Shares Outstanding697.7Mmir.v shares outstanding · mir.v floatShares outstanding history
Next EarningsJun 30, 2026Est.mir.v earnings date · mir.v next earningsEarnings history

财务快照

完整财报
FY 2025Revenue$240509.00▼ 41.70% YoY
202320242025
medmira inc. revenue · mir.v revenue 2025
FY 2025Net Income-$4.5M▼ 36.02% YoY
202320242025
medmira inc. net income · mir.v profit 2025
FY 2025EPS$-0.01▼ 35.42% YoY
202320242025
mir.v eps · medmira inc. earnings per share 2025
TTM:Revenue: $188496.00Net Income: -$3.5MEPS: $-0.01View income statement →

股票表现

完整历史
1D+0.00%
1W+9.09%
1M+9.09%
3M-7.69%
YTD-7.69%
1Y-25.00%
5Y-62.50%

关于 MedMira Inc.

CEOHermes Chan
IPO DateDec 1, 1999
Employees52
CountryCA

MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations…

what is medmira inc. · mir.v stock overview · medmira inc. company profile · who is medmira inc. ceo · mir.v TSXV · medmira inc. headquarters · medmira inc. business segments

关于股票概览与关键数据

MedMira Inc.(MIR.V)是 Biotechnology 行业的 Healthcare 类公司,于 Dec 1, 1999 在 TSXV 上市。截至最近交易日,MIR.V 股价为 $0.06,市值约为 $42.1M。过去12个月累计回报 -25.00%,年初至今回报 -7.69%。

2025 财年 MedMira Inc. 营收 $240509.00。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,MedMira Inc.(MIR.V)股价为 $0.06,在 TSXV 上市,52周区间为 $0.05 – $0.11。

MIR.V 最新股价MIR.V quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 9, 2026本内容不构成投资建议